Scope of U.S. Patent 8,426,399: Oral ethyl eicosapentaenoate triglyceride-lowering methods with minimal DHA/LDL impact
Executive summary: U.S. Patent 8,426,399 is directed to a clinical method claim covering oral administration of an omega-3 fatty acid composition dominated by ethyl eicosapentaenoate (EPA) with substantially no docosahexaenoic acid (DHA) or DHA esters, dosed at about 4 g/day of the composition for at least about 12 weeks in subjects with baseline fasting triglycerides in a broad 500 to 1,500 mg/dL window, aiming to reduce triglycerides while avoiding a substantial LDL-C increase versus an untreated (or non-exposed) control receiving concurrent lipid-altering therapy. Dependent claims narrow to dosing frequency (1 to 4 times/day), capsule dosage form, and specific baseline lipid subranges (LDL-C, non-HDL-C, total cholesterol, VLDL-C, HDL-C) plus specific outcome thresholds for triglycerides (≥10% and ≥25%), and additional endpoints including apolipoprotein B and VLDL-C reductions.
What does U.S. Patent 8,426,399 claim and how broad is the method scope?
Claim 1 is the core independent method claim. It has four main technical/evidentiary pillars: (i) patient selection by baseline triglycerides, (ii) dose and administration route/duration, (iii) composition makeup (high EPA ethyl ester purity, no meaningful DHA), and (iv) a comparative clinical effect constraint tying triglyceride reduction to “without substantially increasing LDL-C.”
1) Patient population limitations: baseline triglycerides and lipid context
- Baseline fasting triglycerides: “median fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl.”
- Two-group construct: a first group receiving the composition and a second group who have not received the composition and receive “concurrent lipid altering therapy.”
- LDL-C contextual boundary appears in dependent claim 4:
- baseline LDL-C “from about 40 mg/dl to about 115 mg/dl.”
Scope impact: The “median fasting baseline triglyceride level” language is consistent with clinical study designs (group-level median). It broadens applicability beyond a single individual’s triglyceride value, while still requiring the trial population’s baseline to fall within the defined range.
2) Composition limitation: at least ~96% by weight of all fatty acids, ethyl eicosapentaenoate, substantially no DHA
Claim 1 requires a pharmaceutical composition comprising:
- At least about 96%, by weight of all fatty acids present, ethyl eicosapentaenoate
- “substantially no docosahexaenoic acid or its esters.”
Scope impact:
- The “at least about 96%” purity constraint is a high-percentage constraint on the fatty-acid fraction. It targets a highly EPA-leaning product.
- “Substantially no DHA or its esters” functions as a relative exclusion. In enforcement terms, it invites an accused-product analysis tied to measured DHA content and the interpretation of “substantially.” The breadth is narrower than generic “omega-3” claims but broad enough to cover products with trace DHA below the asserted threshold used in litigation.
3) Route, dose, and duration
- Route: orally administered.
- Dose: “about 4 g per day” of the pharmaceutical composition.
- Duration: “at least about 12 weeks.”
Scope impact: This is a dosing-and-time anchored method. Products using materially different daily amounts, different active dosage basis (EPA-only vs composition amount), or shorter durations may fall outside claim coverage.
4) Comparative endpoint requirement: triglyceride reduction without substantial LDL-C increase
Claim 1 requires effect:
- “to effect a reduction in triglycerides”
- “without substantially increasing LDL-C compared to” the second group.
Scope impact: This is a “balancing” clinical limitation. It makes triglyceride lowering necessary, but it also makes the LDL effect part of what must be shown “compared to” the control group. A product that reduces triglycerides but elevates LDL-C “substantially” is structurally excluded by the claim text.
How do dependent claims narrow coverage (capsule form, dosing frequency, baseline lipid ranges)?
Claim 2: 1–4 times per day
- Composition administered to members of the first group and second group 1 to 4 times per day.
Scope impact: If a regimen is once daily, twice daily, three times, or four times daily, it fits. Regimens requiring more frequent dosing or different scheduling may avoid the claim.
Claim 3: capsule dosage form
- “present in one or more capsules.”
Scope impact: This narrows the method to capsule dosage forms. A liquid formulation, sachet powder, or enteric granulate not in capsules may avoid claim 3 while still potentially infringing claim 1 depending on how “pharmaceutical composition” is interpreted at the independent claim level (claim 1 does not explicitly require capsules).
Claim 4: LDL-C baseline range 40–115 mg/dL
- Baseline fasting LDL-C: 40 to 115 mg/dL (approximate ranges).
Scope impact: This narrows the patient selection to a typical dyslipidemia range. If an accused method uses a population whose baseline LDL-C median falls outside that range, claim 4 is not met, though claim 1 might still be asserted if claim 1’s LDL condition is not required.
Claim 5: additional baseline lipid medians
Claim 5 requires one or more of:
- non-HDL-C: ~200 to 300 mg/dL
- total cholesterol: ~250 to 300 mg/dL
- VLDL-C: ~140 to 200 mg/dL
- HDL-C: ~10 to 80 mg/dL
Scope impact: “One or more” means claim 5 is satisfied if any single lipid median lies in the listed range. This makes claim 5 broad within its added selection framework.
What clinical results must be demonstrated for infringement: triglyceride percent reduction, apoB, VLDL-C?
Claim 1 requires “reduction in triglycerides” plus “without substantially increasing LDL-C.” Dependent claims specify magnitude and additional endpoints.
Claim 6: ≥10% fasting triglyceride reduction without substantial LDL-C increase
- Daily ~4 g composition for ≥12 weeks
- Achieve fasting triglycerides reduction of at least about 10%
- Without substantially increasing LDL-C
Claim 7: ≥25% fasting triglyceride reduction without substantial LDL-C increase
- Same dosing and duration
- Achieve fasting triglycerides reduction of at least about 25%
- Without substantially increasing LDL-C
Scope impact: These dependent claims are outcome-quantified. In a patent dispute, they can become claim-chart leverage because trial endpoints and statistical comparisons are typically documented. A product could arguably reduce triglycerides but not to the thresholds required for claims 6 or 7.
Claim 8: apolipoprotein B reduction
- Same dosing and duration structure
- Reduce apolipoprotein B
Scope impact: This can matter in markets where apoB reduction is part of labeling or clinical differentiation. It also provides an additional infringement theory if triglyceride reduction is contested.
Claim 9: VLDL-C reduction
- Same dosing and duration structure
- Reduce VLDL-C
Scope impact: VLDL-C is closely linked to triglyceride metabolism, so VLDL-C reduction may be easier to connect mechanistically than apoB in some clinical datasets.
What is the effective “composition boundary” between EPA-only and mixed omega-3 products?
The key exclusion is DHA. Claim 1 requires “substantially no docosahexaenoic acid or its esters,” and at least about 96% of fatty acids by weight are ethyl eicosapentaenoate.
Implications for generic or reformulated products
- Products that include meaningful DHA (for example, standard mixed fish oil omega-3 combinations) face a compositional mismatch.
- Products that use ethyl-EPA but include DHA above a litigation-argued “substantially no” threshold also risk non-infringement.
Implications for “composition is what’s dosed” ambiguity
The claim is framed around “administering orally to the subjects about 4 g per day of a pharmaceutical composition” meeting the EPA/DHA criteria. If an accused regimen is engineered so that “4 g/day” refers to EPA content rather than total composition mass, the boundary becomes evidentiary: does the administered mass meet “about 4 g per day” as claimed? If a company seeks design-around, this is a dosing-unit alignment issue.
What does the two-group comparative language require for proof?
Claim 1’s comparator is the “second group of subjects” that:
- has similar baseline triglycerides (“median fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl”)
- has not received the pharmaceutical composition
- has concurrent lipid altering therapy.
Scope impact:
- The claim is designed for a controlled clinical comparison model, even if enforcement could be framed as method performance in a study.
- In practice, infringement arguments often map to whether the observed results in the treated group show triglyceride reduction and “no substantial LDL-C increase” versus an appropriate control group under similar background lipid-altering therapy.
Why the LDL-C limitation is central to the patent’s business value
The claim includes an LDL-C condition in two places:
- Independently in claim 1 (“without substantially increasing LDL-C compared to” second group)
- Repeated in dependent claims 6 and 7.
Business implication: The patent targets a safety-balance problem that matters for omega-3 therapies: triglyceride lowering versus LDL-C elevation risk. The claim’s comparative structure is built to support differentiation in labeling or clinical practice and to reduce the risk of infringement-by-effect disputes hinging on LDL outcomes.
Which product classes are most likely to fall within or outside the claim?
Most likely within
- Oral, capsule-based (if claim 3 pursued) EPA ethyl ester-dominant formulations meeting:
- ≥96% EPA ethyl ester by fatty-acid weight fraction
- substantially no DHA or DHA esters
- dose about 4 g/day of the claimed composition for ≥12 weeks
- patient populations with fasting triglyceride medians ~500–1,500 mg/dL
- demonstrated triglyceride lowering without substantial LDL-C rise vs controlled background lipid therapy
Most likely outside
- Mixed omega-3 products with substantial DHA content.
- Regimens using materially different daily dosing amounts or durations under the “at least about 12 weeks” anchor.
- Dosing schedules not within “1 to 4 times per day” if claim 2 is asserted.
- Non-capsule formulations if claim 3 is asserted.
- Patient-selection mismatches for dependent claims (LDL-C median outside 40–115 mg/dL, etc.), though claim 1 may still be asserted if those medians are not required by the independent claim.
Key takeaways on claim leverage and patent estate focus for U.S. 8,426,399
- Composition purity is the first gate: the claim is not “omega-3s” broadly; it is ethyl eicosapentaenoate-dominant with substantially no DHA/DHA esters and ≥96% by fatty-acid weight.
- Clinical outcome is inseparable from composition: triglyceride lowering alone is insufficient; “without substantially increasing LDL-C” is part of claim 1 and reinforced in claims 6 and 7.
- Dose-and-duration anchored: ~4 g/day for at least ~12 weeks is a hard boundary for method performance.
- Patient-selection is bounded but uses medians: the baseline triglyceride window is set using “median fasting baseline” ranges, aligning the claim to trial-group characteristics.
- Dependent claims add proof points: triglyceride percent reductions (≥10%, ≥25%), apoB reduction, and VLDL-C reduction create multiple enforcement routes once composition and dosing match.
- Dosage form and scheduling provide layered design-around options: capsules and 1 to 4 times/day are dependent claim constraints, which can be relevant for product development strategy.
FAQs
What LDL-C change qualifies as “substantially increasing” under U.S. 8,426,399?
The claim text uses the qualitative “without substantially increasing LDL-C.” Practical infringement analysis turns on how LDL-C is measured and statistically compared versus the second group in a controlled setting using the trial’s background lipid-altering therapy.
Does U.S. 8,426,399 cover DHA-containing EPA mixtures?
Claim 1 requires “substantially no docosahexaenoic acid or its esters” and ≥96% EPA ethyl ester by fatty-acid weight, which excludes products with meaningful DHA content.
Is 8,426,399 limited to triglyceride reductions only in severe hypertriglyceridemia?
No. It covers baseline median fasting triglycerides from about 500 to about 1,500 mg/dL, which spans moderate to severe ranges.
Can an accused regimen infringe claim 1 if it is not given as capsules?
Claim 1 does not require capsules. If capsules are used only in claim 3, then non-capsule formulations may avoid claim 3 but could still be evaluated against claim 1’s broader method and composition limitations.
What evidence is most persuasive for claims 6 and 7 (10% vs 25% triglyceride reduction)?
Fasting triglyceride percent change data in the treated group versus the control group under comparable background lipid therapy, over at least 12 weeks, mapped directly to the claim’s thresholds.
References
- United States Patent 8,426,399.
